No products in the cart.
Rabbit Polyclonal Phospho-Tau (S516/199) antibody (STJ90658)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, ELISA
Recommended dilution: WB 1:500-1:2000; ELISA 1:40000;
Recommended protocols: check protocols
Click or hover above images to see image description for Tau (phospho Ser516/199) Polyclonal Antibody.
Check alternative names for the antibodyExpand
MAPT antibody, MAPTL antibody, MTBT1 antibody, TAU antibody,|FTDP17 antibody|Microtubule associated protein tau antibody|Paired helical filament tau antibody|PHF tau antibody|PPND antibody|TAU antibody|Anti-Tau 13 antibody [B11E8] (ab19030)
SCBT cat No: sc-66177|sc-271076|sc-5863|sc-166114|sc-166314|sc-28240|sc-166332|sc-5860|sc-80900|sc-53596|sc-18167|sc-365091|sc-514453|sc-15323|sc-14116|sc-14115|sc-5218|sc-5220|sc-14121|sc-22050|sc-28951|sc-14128|sc-28952|sc-168757|sc-161946|sc-161948|sc-20980|sc-514774|sc-21547|
Tau (phospho Ser516/199) Polyclonal Antibody
|Catalogue No.|| |
Human, Mouse, Rat
Phospho-Tau (S516/199) Polyclonal Antibody detects endogenous levels of Tau protein only when phosphorylated at S516/199.
Synthesized phospho-peptide derived from Tau (phospho Ser516/199) at AA range 140-220
|Recommended dilution|| |
WB 1:500-1:2000; ELISA 1:40000;
|Molecular weight|| |
Tau (phospho Ser516/199) Antibody was tube-contained. Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Tau (phospho Ser516/199) Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
Microtubule-associated protein tau antibody, Neurofibrillary tangle protein antibody, Paired helical filament-tau antibody, PHF-tau antibody
|Protein names|| |
Microtubule-associated protein tau , Neurofibrillary tangle protein , Paired helical filament-tau , PHF-tau
|Involvement in disease|| |
Note: In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). O-GlcNAcylation is greatly reduced in Alzheimer disease brain cerebral cortex leading to an increase in TAU/MAPT phosphorylations. .; Frontotemporal dementia (FTD) [MIM:600274]: A form of dementia characterized by pathologic finding of frontotemporal lobar degeneration, presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Pick disease of the brain (PIDB) [MIM:172700]: A rare form of dementia pathologically defined by severe atrophy, neuronal loss and gliosis. It is characterized by the occurrence of tau-positive inclusions, swollen neurons (Pick cells) and argentophilic neuronal inclusions known as Pick bodies that disproportionally affect the frontal and temporal cortical regions. Clinical features include aphasia, apraxia, confusion, anomia, memory loss and personality deterioration. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Note: Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease.; Progressive supranuclear palsy 1 (PSNP1) [MIM:601104]: Characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. . Note: The disease is caused by mutations affecting the gene represented in this entry.; Parkinson-dementia syndrome (PARDE) [MIM:260540]: A syndrome characterized by parkinsonism, tremor, rigidity, dementia, ophthalmoparesis and pyramidal signs. Neurofibrillary degeneration occurs in the hippocampus, basal ganglia and brainstem nuclei. Note: The disease is caused by mutations affecting the gene represented in this entry.
AntibodyPlus can customize Tau (phospho Ser516/199) Antibody according to your requirement, including bulk product size,etc. Please contact email@example.com. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: